Stock screener
All disclosures →
EDGAR →
ALKS
Conviction 47HealthcareScan · Thu, Sep 24, 2026Alkermes plc. (ALKS) closed at $40.80 (-3.17%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 25, RS Rating 83, -26.1% from its 52-week high, +44.4% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
ALKS$40.80-3.17%
ResistanceSupportVol 14Insider sellCongress buyCongress sell2
Vol MA14 2.42M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price40.80
Change-3.17%
Gap-0.93%
Rel volume2.35×
Avg volume2.13M
Avg $ vol95.7M
SMA 2045.63
SMA 5048.35
SMA 20038.73
Price vs 50-15.63%
Price vs 200+5.33%
MA stackmixed
50/200 cross—
Supertrenddown · 46.24
RSI (14)25
MACD hist-0.42
MACD crossbear · 4d
Stoch %K / %D3 / 6
ADX (14)26
+DI / −DI12 / 36
RSI divergence—
MACD divergence—
ATR %3.95%
ADR %3.28%
52w high55.22
52w low27.13
From 52w high-26.12%
Above 52w low+50.37%
New 52w highNo
SqueezeOff
Bollinger width16.92%
%B-0.13
Donchian pos2.23%
Donchian high49.33
Donchian low40.60
AVWAP (52w high)48.34
vs AVWAP high-15.61%
AVWAP (52w low)36.65
vs AVWAP low+11.30%
OBV trendDown
Chaikin MF (20)-0.28
Today vs 20d2.35×
Avg vol (14d)2.42M
Avg vol (20d)2.13M
Avg $ vol (20d)95.7M
Market cap6.84B
RS Rating83 / 99
RS 3m (vs SPY)-27.27%
RS 6m (vs SPY)+22.08%
RS line new highNo
Trend template4/8
Technical rank52.7
1 week-12.66%
1 month-17.10%
3 months-22.78%
6 months+38.90%
1 year+47.01%
YTD+44.36%
P/E28.32
P/B3.78
P/S4.64
P/FCF14.25
EPS1.43
Div yield—
ROE13.36%
ROA5.50%
Debt/Eq0.83
Current2.30
EV/EBITDA27.87
Gross margin—
Net margin16.37%
Rev growth-5.25%
EPS growth-34.16%
Price target59.08
Target upside44.82%
Analyst ratingBuy
Institutional121.80%
Ent. value7.84B
Revenue496.01M
Net income501K
Gross profit—
Free cash flow480.33M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out166.68M
Employees2.05K
ListedTue, Jul 16, 1991
Free float162.41M
Float %98.4%
Short interest14.72M
Days to cover11.8d
Short volume36.3%
Squeeze score58 / 100
Next earnings—
EPS forecast—
Last EPS vs est$0.00 vs −$0.04
Last surprise+100.0% beat
Setup gradeC
Conviction47 / 100
Pattern quality—
Tech rank52.7 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance51.48
Support44.63
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Goldman Sachs resumes Alkermes stock coverage with neutral ratingInvesting.com · Thu, Sep 24, 2026
- ALKS Looks 29.1% Overvalued on GF Value™GuruFocus · Thu, Sep 24, 2026
- ALKS261016P00041000 Interactive Stock Chart | ALKS Oct 2026 41.000 put StockYahoo Finance · Thu, Sep 24, 2026
- ALKS270219P00041000 Interactive Stock Chart | ALKS Feb 2027 41.000 put StockYahoo Finance · Wed, Sep 23, 2026
- ALKS Oct 2026 55.000 call (ALKS261016C00055000) stock price, news, quote and historyYahoo Finance UK · Wed, Sep 23, 2026
- ALKS Oct 2026 55.000 call (ALKS261016C00055000) Interactive Stock Chart - Yahoo FinanceYahoo! Finance Canada · Wed, Sep 23, 2026
- ALKS Oct 2026 45.000 call (ALKS261016C00045000) stock historical prices and dataYahoo Finance Australia · Wed, Sep 23, 2026
- ALKS261016P00042000 Interactive Stock Chart | ALKS Oct 2026 42.000 put StockYahoo Finance · Wed, Sep 23, 2026
- ALKS Oct 2026 42.000 put (ALKS261016P00042000) stock price, news, quote and historyYahoo Finance Singapore · Wed, Sep 23, 2026
- Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290Yahoo Finance · Wed, Sep 23, 2026
Congress activity
Disclosed STOCK Act trades in ALKS · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
Gilbert Cisneros house · D · CA · traded 2026-07-30 | Buy | $15K–$50K | 2026-07-30 | 2026-09-04 |
Insider activity
SEC Form 4 transactions in ALKS · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Ordinary Shares · 2026-09-01 | Sell | 9K | $423K | 2026-09-01 | 2026-09-01 |
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Ordinary Shares · 2026-09-01 | Exercise | 5K | $123K | 2026-09-01 | 2026-09-01 |
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Employee Stock Option (Right to Buy) · 2026-09-01 | Exercise | 5K | — | 2026-09-01 | 2026-09-01 |
Nichols Christian Todd SVP, Chief Commercial Officer · Ordinary Shares · 2026-08-17 | Sell | 6.91K | $340K | 2026-08-17 | 2026-08-17 |
Nichols Christian Todd SVP, Chief Commercial Officer · Ordinary Shares · 2026-08-17 | Sell | 664 | $33K | 2026-08-17 | 2026-08-17 |
Jackson Blair Curtis President & CEO, Alkermes plc · Employee Stock Option (Right to Buy) · 2026-08-05 | Grant | 93.23K | — | 2026-08-05 | 2026-08-07 |
Jackson Blair Curtis President & CEO, Alkermes plc · Employee Stock Option (Right to Buy) · 2026-08-05 | Grant | 124.31K | — | 2026-08-05 | 2026-08-07 |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. · Ordinary Shares · 2026-07-06 | Sell | 2.03K | $110K | 2026-07-06 | 2026-07-06 |
Wright Christopher I Director · Ordinary Shares · 2026-06-12 | Sell | 2K | $90K | 2026-06-12 | 2026-06-12 |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. · Ordinary Shares · 2026-06-04 | Sell | 2.03K | $88K | 2026-06-04 | 2026-06-04 |
SEC filings
EDGAR filings in ALKS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.